NKNathella Pavan Kumar

Nathella Pavan Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nathella Pavan Kumar has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Animal Models for Post-Tuberculosis Lung Disease: Translational Gaps, Mechanistic Insights, and Future Directions

    by Vaishnavi Vivekanandan, Arun K, Nathella Pavan Kumar, Kannan Palaniyandi

    Successful tuberculosis (TB) treatment does not necessarily restore pulmonary health, and many TB survivors develop persistent structural and functional lung abnormalities known as post-tuberculosis lung disease (PTLD). Despite its clinical significance, the mechanisms underlying PTLD remain poorly understood, and effective therapies are lacking. Progress is impeded by the absence of preclinical models that adequately reproduce post-treatment features of pulmonary TB. This narrative review evaluates established animal TB models, such as murine, guinea pig, rabbit, and non-human primate models, and their relevance to PTLD research. We assessed their ability to replicate lung pathology, such as fibrosis, cavitation, extracellular matrix remodeling, and persistent inflammation. Additionally, we examined the mechanisms of TB-associated lung injury, including immune dysregulation, matrix metalloproteinase activity, and profibrotic signaling. However, these pathological processes have been studied predominantly during active infection, and their contributions to persistent lung damage following treatment remain insufficiently characterized in existing preclinical models. Major translational gaps include limited emphasis on post-treatment disease, inadequate longitudinal assessment of lung function, and the absence of standardized criteria for defining PTLD in preclinical studies. Finally, we underscore the need for longitudinal animal models incorporating treatment outcomes and clinically relevant endpoints to bridge experimental findings with the persistent pulmonary consequences experienced by TB survivors.

  • Identification of plasma immune markers associated with latent tuberculosis conversion in HIV-infected individuals who received isoniazid preventive therapy

    by Nathella Pavan Kumar, Guruprashath Mohan, Agalya Vanamudhu, Sivasubarmanian K, Kannan T, Y Savari Silvester, Bubby S Kumar, Janakiram M, Vinod Kumar, Vijila S, et al.

  • Open Access

    Prognostic utility of immune biomarkers for identifying individuals at risk of unfavourable treatment outcomes in pulmonary tuberculosis

    by Agalya Vanamudhu, Vijay Viswanathan, Guruprashath Mohan, Nivedha Krishna Rao, Kannan Thiruvengadam, Syed Hissar, Bhavani Permal Kannabiran, Subash Babu, Hardy Kornfeld, Nathella Pavan Kumar

    Introduction: Tuberculosis remains a major global health challenge, with many patients expe- riencing unfavourable treatment outcomes despite standard therapy. Host immune biomarkers, including cytokines, chemokines, and matrix metalloproteinases (MMPs), have shown promise in predicting disease severity and treatment response, but require validation across independent cohorts. Methods: We validated previously identified immune biomarkers using baseline plasma samples from a nested case–control cohort within the RePORT India consortium (cases: n=74; controls: n=161). Cytokines (IL-2, IFN-γ, TNF-α, IL-6, IL-1β, IL-10, IL-17A, and GM-CSF), chemokines (CCL2, CCL3, CCL4, CXCL1, CXCL8, and CXCL10), and matrix metalloproteinases (MMP-1, MMP-2, MMP-7, and MMP-9) were quantified using multiplex ELISA on the Luminex platform. Statistical analyses included group comparisons, ROC analysis, logistic regression, random forest modelling, princi- pal component analysis, and stability selection to identify optimal biomarker combinations. Results: Elevated levels of IL-2, IFN-γ, TNF-α, IL-6, CCL2, CXCL8, CXCL10, MMP-2, MMP-7, and MMP-9 were associated with unfavourable out- comes. IL-2, CXCL8, CCL2, and MMP-2 showed strong individual predictive performance (AUC ≥0.80). Multivariable analysis identified CCL2, CXCL8, and CXCL10 as significant predictors of poor outcomes. A combined biomarker panel comprising CXCL8, MMP-2, and CCL2 demonstrated excellent predictive accu- racy (AUC ~0.90), with sensitivity ranging from 89% to 98% and specificity ranging from 80% to 90%, depending on the biomarker combination and the selected ROC cut-off. Discussion: These findings validate key immune biomarkers and support a multi- marker host biomarker panel for early risk stratification and personalized TB management.

  • Open Access

    Integrated Profiling of TNF Superfamily Ligands and Lung Inflammatory Markers in Tuberculosis-Type 2 Diabetes Mellitus Comorbidity

    by Nandita Ganesh, Rajesh Kumar Radhakrishnan, Fathima Sumaira, Jai Priya Govindasamy Venugopal, Bhavani Perumal Kannabiran, Uma Devi Ranganathan, Syed Hissar, Ramakrishna Vankayalapati, Nathella Pavan Kumar

    Background: Type 2 diabetes mellitus (T2DM) increases susceptibility to tuberculosis (TB) and contributes to immune dysregulation, exaggerated inflammation and poor clinical outcomes. Acute-phase proteins (APPs), lung-associated markers (LMs) and TNF superfamily ligands play a crucial role in inflammatory and immune signaling; however, an integrated approach in understanding the inflammatory profile and their immunological association in TB-T2DM remains underexplored. Methods: Plasma levels of APPs and LMs including CRP, SAA1, Haptoglobin, α2M, IDO, CHI3L1, S100A8, S100A9 and granulysin were evaluated for the study cohort of 176 individuals (TB = 44, TB–T2DM = 44, T2DM-only = 44 and healthy-controls = 44). TNF superfamily ligands, including 4-1BBL, APRIL, BAFF, CD30L, CD40L, EDA-1, Fas-L, GITRL, LIGHT, RANKL, NGF- β, TNF-β, TRAIL and TWEAK, were measured using a multiplex immunoassay for 88 individuals (TB = 22, TB–T2DM = 22, T2DM-only = 22 and healthy-controls = 22). Spearman correlation analysis, protein–protein interaction (PPI) network analysis and pathway enrichment analysis were also performed. Results: TB-T2DM individuals exhibited significantly increased inflammatory burden compared with TB, T2DM and HC groups. Increased levels of CRP, SAA1, S100A8, S100A9, haptoglobin, CH3IL1 and α2M were observed (p < 0.05), indicating amplified systemic and pulmonary inflammation. TNF superfamily ligands including BAFF, APRIL, CD40L, GITRL, LIGHT and TRAIL were significantly altered in TB-T2DM individuals, suggesting dysregulated TNF-mediated immune signaling. Correlation analysis revealed strong associations between HbA1c levels and inflammatory markers including BAFF, TRAIL, GITRL, LIGHT, CD40L, APRIL, S100A8 and SAA1 (p < 0.05). Network and enrichment analyses identified significant involvement of cytokine–cytokine receptor interaction, IL-17 signaling, NF-κB signaling, apoptosis and necroptosis pathways. Conclusions: Overall, TB-T2DM comorbidity is characterized by exaggerated inflammatory responses and altered TNF superfamily ligand signaling associated with poor glycemic control. This interconnected immune dysregulation may provide future insights into biomarkers and pathway-related investigation to establish more clinical and biological relevance.

  • Open Access

    Profiling complement proteins in pediatric tuberculosis children with or without serological evidence of prior SARS-CoV-2 exposure

    by Nathella Pavan Kumar, Guruprashath Mohan, Sarath Balaji, Agalya Vanamudhu, Prabhakar R, Balaji Ramraj, Poorna Ganga Devi, Shaik Fayaz Ahamed, Karthik M, Gopika S, et al.

    Introduction: Coinfection with Mycobacterium tuberculosis (TB) and SARS-CoV-2 poses unique challenges in pediatric population due to overlapping immune pathways and potential immune dysregulation. The complement system, a key arm of innate immunity, plays a dual role in pathogen clearance and inflammation. Methods: This study aimed to investigate complement activation in TB in children with or without serological evidence of prior SARS-CoV-2 exposure. Children aged 2–17 years with pulmonary or extrapulmonary TB were recruited from two tertiary hospitals in South India. Participants were grouped based on SARS-CoV-2 IgG serostatus: CoV2⁺ (n = 30) and CoV2⁻ (n = 30). Blood samples were collected at baseline, and at months 3, and 6 for complement profiling. Levels of classical, lectin, and alternative pathway proteins, as well as regulatory factors, were quantified using multiplex bead-based assays. Canonical discriminant analysis (CDA) and Spearman correlation were used to analyse temporal and relational patterns in complement activation. Results: CoV2 + children had significantly elevated levels of classical pathway proteins (C1q, C3, C4, C5a) and regulatory factors (Factor B, H, and I) at baseline, month 3 and month 6 in comparison to CoV2 - children. However C2 and C5 diminished in CoV2 + children in comparison to CoV2-CDA revealed distinct, time-resolved complement activity in CoV2⁻ children, whereas CoV2⁺ profiles showed overlap, suggesting prolonged immune alteration. Correlation analysis identified significant associations between SARS-CoV-2 IgG and complement proteins, with differing patterns in CoV2 + and CoV2 - groups over time. Discussion: SARS-CoV-2 seropositivity may contribute to changes in the complement activation trajectory in TB-diseased children, potentially contributing to persistent inflammation. Complement profiling may inform therapeutic strategies and serve as a biomarker of immune recovery in TB– SARS-CoV-2 co-infection.

  • Open Access

    Complement profiling for treatment outcomes in pulmonary TB

    by Nathella Pavan Kumar, Arul Nancy P., Syed Hissar, Shanmugam Sivakumar, Vijay Viswanathan, Ramalingam Bethunaickan, Hardy Kornfeld, Subash Babu

    Introduction: The complement system plays a vital role in the immune response against tuberculosis (TB), aiding in the recognition and clearance of Mycobacterium tuberculosis. However, its imbalance can result in either insufficient immune activation or excessive inflammation, both of which may contribute to poor treatment outcomes. Methods: This study investigates whether baseline complement profiles are associated with unfavorable treatment responses in pulmonary TB patients. Using the Magpix multiplex cytokine assay, plasma levels of complement components (C2, C3, C3b/iC3b, C4, C4b, C5, C5a, C1q, MBL) and regulatory proteins (Factor B, Factor D, Factor H, Factor I) were measured in TB patients with poor treatment outcomes (n=68) and disease-free controls (n=108). Results: At both baseline (pre-treatment) and month two of anti-TB therapy, cases had significantly elevated levels of C3, C3b, C4b, C5, C5a, and C1q, and reduced levels of Factor B and Factor H compared to controls. Regression modelling revealed that C3, C3b, C4b, C5, C5a and C1q were associated with increased risk of unfavorable outcomes in unadjusted and adjusted analyses in the study cohort. Discussion: These findings suggest that early and sustained complement activation, particularly through the classical pathway, is associated with adverse outcomes in TB. Complement dysregulation may thus serve as a potential prognostic marker for identifying individuals at risk of poor treatment response.


  • Open Access

    Plasma Matrix Metalloproteinases Signature as Biomarkers for Pediatric Tuberculosis Diagnosis: A Prospective Case–Control Study

    by Nathella Pavan Kumar, Syed Hissar, Arul Nancy, Kannan Thiruvengadam, Velayuthum V. Banurekha, Sarath Balaji, S. Elilarasi, N. S. Gomathi, J. Ganesh, M. A. Aravind, et al.

    Diagnosing tuberculosis (TB) in children presents significant challenges, necessitating the identification of reliable biomarkers for accurate diagnosis. In this study, we investigated plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) as potential diagnostic markers. A prospective case–control study involved 167 children classified into confirmed TB, unconfirmed TB, and unlikely TB control groups. Plasma levels of MMPs (MMP 1, 2, 3, 7, 8, 9, 12, and 13) and TIMPs (TIMP 1, 2, 3, and 4) were measured using multiplex assays. Elevated baseline levels of MMP-1, MMP-2, MMP-7, MMP-9, TIMP-1, TIMP-2, TIMP-3, and TIMP-4 were observed in active TB cases compared to unlikely TB controls. Receiver operating characteristics (ROC) analysis identified MMP-1, MMP-2, MMP-9, and TIMP-1 as potential biomarkers with over 80% sensitivity and specificity. A three-MMP signature (MMP-1, MMP-2, and MMP-9) demonstrated 100% sensitivity and specificity. The findings suggest that a baseline MMP signature could serve as an accurate biomarker for diagnosing pediatric TB, enabling early intervention and effective management.


  • Open Access

    Acute-phase proteins as biomarkers of inflammation in HIV patients with latent tuberculosis: a prospective study

    by Nathella Pavan Kumar, Rajamariyam M, Arul Nancy, Bubby S. Kumar, Janakiram M, Shaik Fayaz Ahamed, Vinod Kumar, Vijila S, Sekar S, Kuralmozhi R, et al.

    Introduction: Tuberculosis (TB) remains the primary cause of death among individuals infected with HIV, increasing the risk of contracting TB by up to 26 times. This co-infection complicates the diagnosis and treatment of TB, ultimately affecting outcomes adversely. Acute-phase proteins (APPs), markers of inflammation, are significantly elevated during infections and serve as critical indicators of inflammation resulting from infectious diseases.Methods: In this prospective study, HIV-positive individuals at antiretroviral therapy (ART) clinics were screened for latent tuberculosis infection (LTBI) before starting isoniazid (INH) prophylaxis. Initially, 101 patients were enrolled, with 71 completing a six-month follow-up on INH prophylaxis. LTBI was diagnosed using QuantiFERON-TB Gold plus, categorizing participants as HIV-positive with LTBI (n=30) and HIV-positive without LTBI (n=71).Results: Plasma levels of alpha-2-macroglobulin (A2M), C-reactive protein (CRP), serum amyloid P (SAP), haptoglobin, ferritin, soluble transferrin receptor (sTFR), apotransferrin, hepcidin, and S100A8/A9 were assessed using multiplex and quantikine assays.At baseline, levels of A2M, CRP, SAP, ferritin, hepcidin, and S100A9 were significantly elevated in HIV-positive patients with LTBI compared to those without LTBI (A2M, p=0.005; CRP, p<0.001; SAP, p=0.0006; ferritin, p<0.001; hepcidin, p=0.001; S100A9, p=0.001). Following six months of INH prophylaxis, significant reductions in these markers were observed in both groups, suggesting a reduction in inflammation.Discussion: Our findings indicate that a baseline profile of APPs can effectively reflect the inflammatory status of HIV patients with LTBI. These inflammatory markers tend to decrease following effective INH treatment, underscoring their potential utility in monitoring disease progression and treatment response in this vulnerable population.


  • Open Access

    Association of Altered Baseline Hematological Parameters with Adverse Tuberculosis Treatment Outcomes

    by Arul Nancy Pandiarajan, Nathella Pavan Kumar, Kadar Moideen, Kannan Thiruvengadam, Syed Hissar, Shanmugam Sivakumar, Ramalingam Bethunaickan, Vijay Viswanathan, Hardy Kornfeld, Subash Babu

    Tuberculosis (TB) treatment monitoring is an essential tool for effective TB treatment management. Identifying parameters that predict adverse TB treatment outcomes could significantly improve clinical management. The association of hematological parameters with poor TB treatment outcomes is not well defined. To study the relationship of hematological parameters with TB treatment outcomes, we examined data from pulmonary tuberculosis (PTB) patients with successful (controls) and unsuccessful (cases) treatment outcomes. We enrolled 68 cases and 133 controls through a nested 1:2 case–control study, matching for age, sex, body mass index, diabetes status, alcohol and smoking. Hematological profiling showed significant difference in the absolute counts of white blood cells, lymphocytes, neutrophils and monocytes between cases and controls. In addition, increased neutrophil to lymphocyte ratio (NL) ratio and monocyte to lymphocyte (ML) ratio were present in cases in comparison to controls. Similarly, decreased hematocrit and red blood cell counts were detected in cases when compared with controls. Univariate and multivariate analysis demonstrated a significant association of absolute counts of WBC, neutrophils, monocytes, NL and ML ratios with poor treatment outcomes. The altered baseline hematological parameters are clearly associated with the poor TB treatment outcomes, showing potential for clinical prediction to enhance management of at-risk cases.

  • Open Access

    Inflammatory cytokine responses in pediatric tuberculosis with or without SARS-CoV-2 seropositivity

    by Nathella Pavan Kumar, Sarath Balaji, Poorna Ganga Devi, Balaji Ramraj, Arul Nancy, Nandhini Selvaraj, Shaik Fayaz Ahamed, Karthik M, Suba S, A. Gunasundari, et al.